# OnCo record ac225-psma (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ac225-psma/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ac225-psma" ;
  schema:name "Actinium-225 PSMA agents"@en ;
  schema:description "Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply."@en ;
  schema:url <https://onco.cc/drugs/ac225-psma/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=225Ac-PSMA-617> ;
  onco:status "phase-3" ;
  onco:modality "Targeted alpha therapy" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/fusion-pharma/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct07590934/> .